Skip to main content
Clinical Trials/JPRN-UMIN000006952
JPRN-UMIN000006952
Completed
Phase 3

A randomised comparison of safety and efficacy of triple therapy for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa 2b and ribavirin in HCV patients - Study of 12 or 36 additional weeks of peginterferon alfa 2b and ribavirin

Hiroshima liver study group0 sites230 target enrollmentDecember 26, 2011

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Hiroshima liver study group
Enrollment
230
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 26, 2011
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hiroshima liver study group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Transient response to prior treatment 2\)Patients receiving shosaiko\-to 3\)Autoimmune hepatitis 4\)History of hypersensitivity to PEG\-IFN alpha\-2b and telaprevir 5\)History of hypersensitivity to biological products such as vaccine 6\)Decompenstated liver cirrhosis 7\)HCC, malignat tumor 8\)With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. 9\)Pregnant or lactating women and women who may be pregnant 10\)Judged by investigator not to be appropriate for inclusion in this study

Outcomes

Primary Outcomes

Not specified

Similar Trials